Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023.

Autor:	Tenforde MW; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Weber ZA; Department of Clinical Resarch, Westat, Rockville, Maryland., Yang DH; Department of Clinical Resarch, Westat, Rockville, Maryland., DeSilva MB; Department of Research, HealthPartners Institute, Minneapolis, Minnesota., Dascomb K; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah., Irving SA; Department of Science Programs, Kaiser Permanente Center for Health Research, Portland, Oregon., Naleway AL; Department of Science Programs, Kaiser Permanente Center for Health Research, Portland, Oregon., Gaglani M; Section of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health and Baylor College of Medicine, Temple, Texas.; Department of Medical Education, Texas A&M University College of Medicine, Temple, Texas., Fireman B; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Lewis N; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Zerbo O; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Goddard K; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Timbol J; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Hansen JR; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California., Grisel N; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah., Arndorfer J; Division of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, Utah., McEvoy CE; Department of Research, HealthPartners Institute, Minneapolis, Minnesota., Essien IJ; Department of Research, HealthPartners Institute, Minneapolis, Minnesota., Rao S; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Grannis SJ; Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana.; School of Medicine, Indiana University, Indianapolis, Indiana., Kharbanda AB; Department of Pediatric Emergency Medicine, Children's Minnesota, Minneapolis, Minnesota., Natarajan K; Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York.; Medical Informatics Services, NewYork-Presbyterian Hospital, New York, New York., Ong TC; Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado., Embi PJ; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee., Ball SW; Department of Clinical Resarch, Westat, Rockville, Maryland., Dunne MM; Department of Clinical Resarch, Westat, Rockville, Maryland., Kirshner L; Department of Clinical Resarch, Westat, Rockville, Maryland., Wiegand RE; Coronavirus and other Respiratory Viruses Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Dickerson M; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Patel P; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Ray C; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Flannery B; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Garg S; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Adams K; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia., Klein NP; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2024 Jul 25; Vol. 230 (1), pp. 141-151.
DOI:	10.1093/infdis/jiad542
Abstrakt:	Background: The 2022-2023 United States influenza season had unusually early influenza activity with high hospitalization rates. Vaccine-matched A(H3N2) viruses predominated, with lower levels of A(H1N1)pdm09 activity also observed. Methods: Using the test-negative design, we evaluated influenza vaccine effectiveness (VE) during the 2022-2023 season against influenza A-associated emergency department/urgent care (ED/UC) visits and hospitalizations from October 2022 to March 2023 among adults (aged ≥18 years) with acute respiratory illness (ARI). VE was estimated by comparing odds of seasonal influenza vaccination among case-patients (influenza A test positive by molecular assay) and controls (influenza test negative), applying inverse-propensity-to-be-vaccinated weights. Results: The analysis included 85 389 ED/UC ARI encounters (17.0% influenza A positive; 37.8% vaccinated overall) and 19 751 hospitalizations (9.5% influenza A positive; 52.8% vaccinated overall). VE against influenza A-associated ED/UC encounters was 44% (95% confidence interval [CI], 40%-47%) overall and 45% and 41% among adults aged 18-64 and ≥65 years, respectively. VE against influenza A-associated hospitalizations was 35% (95% CI, 27%-43%) overall and 23% and 41% among adults aged 18-64 and ≥65 years, respectively. Conclusions: VE was moderate during the 2022-2023 influenza season, a season characterized with increased burden of influenza and co-circulation with other respiratory viruses. Vaccination is likely to substantially reduce morbidity, mortality, and strain on healthcare resources. Competing Interests: Potential conflicts of interest. During the conduct of the study, all Westat- and Kaiser Permanente Northern California Division of Research–affiliated authors reported receiving contractual support from the CDC via payments made to their respective institutions. Additionally, all authors affiliated with Baylor Scott & White Health, Children's Minnesota, Columbia University Irving Medical Center, HealthPartners Institute, Intermountain Healthcare, Kaiser Permanente Center for Health Research, Regenstrief Institute, University of Colorado Anschutz Medical Campus, and Vanderbilt University Medical Center reported receiving contractual support from the CDC during the conduct of the study, via subcontracts from Westat, Inc, with payments made to their respective institutions. Unrelated to the submitted work, the following disclosures were reported from the past 36 months: A. L. N. received grants from Pfizer and Vir Biotechnology; M. N. received grants directly from CDC and from CDC via subcontracts from Abt Associates and Vanderbilt University Medical Center to her institution; C. E. M. received grants AstraZeneca; S. R. received grants from GSK; and N. P. K. received research support from Pfizer, Merck, GlaxoSmithKline, Sanofi Pasteur, and Seqirus. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu